Long-Term Mortality of HIV Patients Following Cryptococcal Infection
Background. Prevalence of cryptococcosis in HIV-positive patients in the developed world has decreased considerably in the modern antiretroviral (ART) era. While early mortality of cryptococcal infection is lower than in non-HIV-infected patients, late mortality in HIV+ patients has not been previously evaluated. Here, we describe the presentation and outcomes of HIV+ patients with cryptococcosis.
Methods. We conducted a retrospective cohort study of patients with HIV infection and cryptococcosis from January 2002 to June 2017 at our institution. Data included demographics, clinical features, diagnostics, and outcomes. Death date was obtained from the hospital system's Medical Informatics database and the Social Security Death Index.
Results. We reviewed 105 HIV+ patients with cryptococcosis. At time of analysis: 55 were living (52.4%), 17 died within 90 days of cryptococcal diagnosis (early mortality, 16.2%), and 33 died after 90 days (late mortality, 31.4%) (Figure 1 ). Late mortality patients were more likely to have known HIV+ status at the time of cryptococcal diagnosis (97%) than living (70.9%) or early mortality (70.6%) (P = 0.03); less likely to be ART adherent (15.2%) than living (43.6%) or early mortality (35.3%) (P = 0.02); less likely to have private insurance (6.1%) than living (34.5%) or early mortality (17.6%) (P = 0.007); and more likely to have Medicaid (51.5%) than living (29.1%) or early mortality (17.6%) (P = 0.03). Presenting symptoms and diagnostics were similar between groups. Prevalence of substance abuse (48.6%) and psychiatric history (31.4%) were high in all groups but not significantly different.
Conclusion. Despite improvements in ART, HIV+ patients have high mortality following cryptococcal infection which persists beyond their initial hospitalization. Identifying patients at higher risk for mortality is critical for successful treatment and outcomes. In our study, nonadherence to ART was associated with a higher risk of dying. Follow-up studies of late mortality in other opportunistic infections would be beneficial. Background. Healthcare associated outbreaks of mucormycosis have been described in the literature. In 2017, the University of Colorado Hospital (UCH) had an increased number of cases of mucormycosis. The objective of this study was to evaluate possible risk factors and weather patterns associated with cases of mucormycosis diagnosed at UCH from 2012 to 2018 in order determine whether the current antifungal prophylaxis used at UCH should be modified.
Review of Mucormycosis Cases at the University of Colorado Hospital
Methods. A retrospective cohort was conducted involving patients >18 years old who were admitted to UCH between 2012 and 2018 and were diagnosed with proven or probable mucormycosis as defined by the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria. Medical records were reviewed, and data were collected on risk factors, antifungal prophylaxis, and mortality outcome. Weather data were collected from the National Centers for Environmental Information (NCEI).
Results. Twenty-five cases of proven or probable mucormycosis were identified. On average patients had at least two risk factors associated with mucormycosis. The most common risk factors included diabetes mellitus (DM) (13 patients), hematologic malignancy or hematopoietic stem cell transplant (HSCT) (11 patients), use of immunosuppressing medications (11 patients), and invasive procedures. (9 patients). At the time of diagnosis, only six patients were on an antifungal with mold activity. Eight patients died during hospitalization. The distribution of cases over time was compared with weather data for Colorado. A cluster of cases occurred in 2013 (6 cases) and in 2017 (8 cases). A majority of cases were diagnosed during the summer and fall months with July being the month with the most number of cases. There were higher levels of precipitation that occurred prior to or during the cluster of cases.
Conclusion. Cases of mucormycosis at UCH were associated with DM, hematologic malignancy/HSCT, use of immunosuppressive therapy, and invasive procedures. The increase of cases seen 2013 and 2017 occurred in the summer and fall months after higher levels of precipitation were observed in Colorado. Providers at UCH may consider modifying antifungal prophylaxis to include mold coverage in patients with >2 risk factors for mucormycosis who are admitted during the summer and fall.
Disclosures Background. Though the rise in number of mucormycosis cases has been reported globally, the rise in India is alarming especially in uncontrolled diabetics. However, multiple gaps exist in the understanding of the disease in this country.
Methods. To describe the epidemiology, diagnosis, treatment practices, and outcome of mucormycosis in India. A single-arm prospective observational study was conducted in the network of 17 tertiary care centres across India during April 2016 through September 2017. All consecutive proven mucormycosis patients were enrolled in this study. Clinical data including risk factors, investigations, and treatment were collected. All isolates and histopathological specimens were sent to Mycology Reference Laboratory at Chandigarh for final identification (phenotypic and sequencing) and drug susceptibility testing.
Results. A total of 474 cases were enrolled between the study period. Rhinoorbito-cerebral mucormycosis was common (42.7%) presentation with 22.8% patients had brain involvement, followed by pulmonary (14.6%), cutaneous (11.8%), isolated renal (3.9%), and intra-abdominal (2.8%) mucormycosis. The underlying disease or predisposing factors were noted in 79.7% cases (84.9% diabetes mellitus, 12.9% steroids, 10.3% trauma or history of surgery, 9.7% malignancy, and 9.2% transplant). The most common agents isolated were Rhizopus species (75.9%, R. arrhizus [74.3%] and R. homothallicus [6.7%]) followed by Apophysomyces variabilis (7.4%), Mucor species (6%), and Lichtheimia corymbifera (4%). The patients were managed by medical therapy in 82.8%, surgery in 56.8% while 51.7% received combined medical and surgical management. Amphotericin B (96.8%) either lipid formulations (65.7%) or conventional form (39.1%) was the common antifungal used. The mortality of patients was 30.4%; of which, 80.3% patients died within 6 weeks of their diagnosis. 24.3% patients left hospital against medical advice while 50.1% survived.
Conclusion. Rhino-orbital-cerebral mucormysosis in uncontrolled diabetics is common presentation in India. R. arrhizus followed by A. variabilis are common species isolated from those patients. Survival was noted only in half of the patients despite increased awareness and diagnosis.
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